Skip to main content

Table 5 WHO Classification: OS of patients with MDS or AML-MRF receiving AZA front-line

From: Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

WHO diagnosis n Median OS, mo 95 % CI, mo p value
AML30-MRF
AML20–30-MRF
MDS-RAEB-II
MDS-RAEB-I
74
61
96
53
13.1
13.5
18.9
23.7
8.6–17.5
10.5–16.5
12.7–25.1
14.4–33.0
0.001a
AML30-MRF
AML20–30-MRF
74
61
13.1
13.5
8.6–17.5
10.5–16.5
0.474
AML20–30-MRF
MDS-RAEB-II
61
96
13.5
18.9
10.5–16.5
12.7–25.1
0.033b
MDS-RAEB-II
MDS-RAEB-I
96
53
18.9
23.7
12.7–25.1
14.4–33.0
0.302
  1. aHR = 1.247; 95 % CI 1.118–1.392
  2. bHR = 1.551; 95 % CI 1.032–2.331
  3. WHO World Health Organization, OS overall survival, MDS myelodysplastic syndrome, AML acute myeloid leukaemia, MRF MDS-related features, AZA azacitidine, CI confidence interval, RAEB refractory anaemia with excess blasts, HR hazard ratio